跳至内容
· 皮肤填充剂
SKU 10368

Ellansé S

有货
容量
2 x 1 mL
制造商
Sinclair Pharma
产地
荷兰
批发价及价格历史仅对已验证账户开放
allpara 仅向持证从业者供货。请登录或申请 B2B 账户,查看实时价格、批量阶梯价及价格历史。

Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, intended for subdermal implantation in the face to correct wrinkles and facial ageing signs or conditions in a lasting way. It is recommended for minimal volume augmentation and offers 18 months of longevity against 24 months for Ellansé M, a difference due to the shorter PCL chain length of its microspheres. The implant combines 30% synthetic Poly-e-caprolactone (PCL) microspheres with a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC); the gel immediately fills areas of volume loss and is resorbed 2 to 3 months after injection, after which the microspheres are progressively replaced by the patient's own collagen, predominantly type I, reshaping facial contours over time. Ellansé S comes as 2 x 1 mL ready-to-use syringes with four 27G needles and is a Class III medical device, CE marked since 2009 under Medical Device Directive 93/42/EEC.

主要优势: Ellansé S

  • Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
  • Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
  • 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of 25 to 50 microns
  • 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
  • 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
  • The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
  • Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
  • Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
  • Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
  • Class III medical device, CE marked since 2009
关键信息
品牌 ELLANSÉ
制造商 Sinclair Pharma
原产国 Netherlands
认证 CE marked since 2009. Class III medical device under Medical Device Directive 93/42/EEC, Annex IX, Rule 8. GMDN 61219. Basic UDI-DI 50600330427180950212191JR
成分 Synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline (PBS), glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier. PCL microsphere diameter 25 to 50 microns. Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
容量 / 规格 1 ml
包装 2 x 1 mL ready-to-use syringes, with four 27G needles included
针头规格 Four 27G needles supplied in the pack, purchased as CE marked devices
使用类型 For professional use: qualified practitioners and clinics only
注射深度 Subdermal implantation in the face, into the subcutaneous fat or hypodermis. Injection modalities are recommended per facial region (upper, mid and lower face) and per area, and depend on the depth of implantation and the desired degree of volume correction
方案 / 疗程 18 months of longevity, against 24 months for Ellanse M. The two options are distinguished only by the initial polymer chain length of the PCL, with the shorter chains in the S variant degrading sooner. Treatment effects vary with the variant used, the practitioner's injection technique, and patient lifestyle and metabolic rate

适应症与专业用途

主要适应症

  • Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
  • Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
  • Minimal volume augmentation, which is the position of Ellanse S within the range

专业用途

This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.

治疗部位

  • Upper face: forehead, temples, brow area
  • Mid face: nose reshaping, cheek augmentation, nasolabial folds
  • Lower face: oral commissures, marionette lines, chin definition, jawline
  • Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area

适用患者

Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation.

作用原理: Ellansé S ​

Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, 25 to 50 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill. Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.

为什么选择在 Allpara 订购

Allpara 提供正品、经过验证的 ELLANSÉ 产品,来自经过严格审核的供应商,具备完整的批次可追溯性和专家支持。我们为诊所和医美专业人士提供CE认证产品、从欧盟仓库快速配送至欧盟各地,以及具有竞争力的专业价格。我们关注的是您患者的安全、满意度和效果,并提供专属售后支持,让您安心无忧。

常见问题

Ellansé S vs Ellansé M: which should a clinic stock?

When comparing Ellansé S vs M, both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for Ellansé S and 24 months for Ellansé M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. Ellansé S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.

How long does Ellansé S last?

Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.

What is Ellansé S made of?

Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, 25 to 50 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.

更多产品: Sinclair

查看制造商

诊所替代选择

全部产品

Ellansé S

有货
CE认证 CE认证 Ellansé S
仅限已验证账户查看价格
请登录或申请 B2B 账户以查看您的价格。
申请 B2B 账户

Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, intended for subdermal implantation in the face to correct wrinkles and facial ageing signs or conditions in a lasting way. It is recommended for minimal volume augmentation and offers 18 months of longevity against 24 months for Ellansé M, a difference due to the shorter PCL chain length of its microspheres. The implant combines 30% synthetic Poly-e-caprolactone (PCL) microspheres with a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC); the gel immediately fills areas of volume loss and is resorbed 2 to 3 months after injection, after which the microspheres are progressively replaced by the patient's own collagen, predominantly type I, reshaping facial contours over time. Ellansé S comes as 2 x 1 mL ready-to-use syringes with four 27G needles and is a Class III medical device, CE marked since 2009 under Medical Device Directive 93/42/EEC.

主要优势: Ellansé S

  • Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
  • Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
  • 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of 25 to 50 microns
  • 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
  • 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
  • The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
  • Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
  • Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
  • Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
  • Class III medical device, CE marked since 2009
关键信息
品牌 ELLANSÉ
制造商 Sinclair Pharma
原产国 Netherlands
认证 CE marked since 2009. Class III medical device under Medical Device Directive 93/42/EEC, Annex IX, Rule 8. GMDN 61219. Basic UDI-DI 50600330427180950212191JR
成分 Synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline (PBS), glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier. PCL microsphere diameter 25 to 50 microns. Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
容量 / 规格 1 ml
包装 2 x 1 mL ready-to-use syringes, with four 27G needles included
针头规格 Four 27G needles supplied in the pack, purchased as CE marked devices
使用类型 For professional use: qualified practitioners and clinics only
注射深度 Subdermal implantation in the face, into the subcutaneous fat or hypodermis. Injection modalities are recommended per facial region (upper, mid and lower face) and per area, and depend on the depth of implantation and the desired degree of volume correction
方案 / 疗程 18 months of longevity, against 24 months for Ellanse M. The two options are distinguished only by the initial polymer chain length of the PCL, with the shorter chains in the S variant degrading sooner. Treatment effects vary with the variant used, the practitioner's injection technique, and patient lifestyle and metabolic rate

适应症与专业用途

主要适应症

  • Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
  • Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
  • Minimal volume augmentation, which is the position of Ellanse S within the range

专业用途

This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.

治疗部位

  • Upper face: forehead, temples, brow area
  • Mid face: nose reshaping, cheek augmentation, nasolabial folds
  • Lower face: oral commissures, marionette lines, chin definition, jawline
  • Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area

适用患者

Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation.

作用原理: Ellansé S ​

Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, 25 to 50 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill. Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.

为什么选择在 Allpara 订购

Allpara 提供正品、经过验证的 ELLANSÉ 产品,具备完整的批次可追溯性、CE认证库存、欧盟范围内快速配送以及专业的售后支持。

常见问题

Ellansé S vs Ellansé M: which should a clinic stock?

When comparing Ellansé S vs M, both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for Ellansé S and 24 months for Ellansé M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. Ellansé S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.

How long does Ellansé S last?

Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.

What is Ellansé S made of?

Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, 25 to 50 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.

更多产品: Sinclair

查看制造商 →
* 专业用途产品。包装可能因批次或市场而异。完整的使用说明和禁忌症请参阅随附的使用说明书。